| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials CT Trialists The Lancet 376 (9753), 1670-1681, 2010 | 4556* | 2010 |
| The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. B Mihaylova, J Emberson, L Blackwell, A Keech, J Simes, EH Barnes, ... Lancet (London, England) 380 (9841), 581-590, 2012 | 2441 | 2012 |
| The economic burden of back pain in the UK N Maniadakis, A Gray Pain 84 (1), 95-103, 2000 | 2227 | 2000 |
| Economic burden of cancer across the European Union: a population-based cost analysis R Luengo-Fernandez, J Leal, A Gray, R Sullivan The lancet oncology 14 (12), 1165-1174, 2013 | 1301 | 2013 |
| Economic burden of cardiovascular diseases in the enlarged European Union J Leal, R Luengo-Fernández, A Gray, S Petersen, M Rayner European heart journal 27 (13), 1610-1619, 2006 | 1137 | 2006 |
| Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial H Mehanna, M Robinson, A Hartley, A Kong, B Foran, T Fulton-Lieuw, ... The Lancet 393 (10166), 51-60, 2019 | 1030 | 2019 |
| European cardiovascular disease statistics 2012 M Nichols, N Townsend, R Luengo-Fernandez, J Leal, A Gray, ... | 996 | 2012 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 954* | 2022 |
| Applied methods of cost-effectiveness analysis in healthcare AM Gray, PM Clarke, JL Wolstenholme, S Wordsworth OUP Oxford, 2010 | 885 | 2010 |
| European cardiovascular disease statistics S Allender, P Scarborough, V Peto, M Rayner, J Leal, ... European Heart Network 3, 11-35, 2008 | 867 | 2008 |
| A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) PM Clarke, AM Gray, A Briggs, AJ Farmer, P Fenn, RJ Stevens, ... Diabetologia 47, 1747-1759, 2004 | 801 | 2004 |
| Knee replacement AJ Price, A Alvand, A Troelsen, JN Katz, G Hooper, A Gray, A Carr, ... The Lancet 392 (10158), 1672-1682, 2018 | 768 | 2018 |
| Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) P Clarke, A Gray, R Holman Medical Decision Making 22 (4), 340-349, 2002 | 623 | 2002 |
| Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial JN Primrose, R Perera, A Gray, P Rose, A Fuller, A Corkhill, S George, ... Jama 311 (3), 263-270, 2014 | 547 | 2014 |
| European cardiovascular disease statistics J Leal, R Luengo-Fernandez, A Gray British Heart Foundation, 2000 | 521 | 2000 |
| Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial DJ Beard, JL Rees, JA Cook, I Rombach, C Cooper, N Merritt, BA Shirkey, ... The Lancet 391 (10118), 329-338, 2018 | 516 | 2018 |
| UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom … AJ Hayes, J Leal, AM Gray, RR Holman, PM Clarke Diabetologia 56, 1925-1933, 2013 | 508 | 2013 |
| Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) A Gray, M Raikou, A McGuire, P Fenn, R Stevens, C Cull, I Stratton, ... Bmj 320 (7246), 1373-1378, 2000 | 484 | 2000 |
| Handling uncertainty when performing economic evaluation of healthcare interventions. AH Briggs, AM Gray Health technology assessment (Winchester, England) 3 (2), 1-134, 1999 | 474 | 1999 |
| Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open … PD Med Collaborative Group The Lancet 384 (9949), 1196-1205, 2014 | 471 | 2014 |
Borislava MihaylovaUniversity of Oxford, Queen Mary University of Londondph.ox.ac.uk의 이메일 확인됨